Press release
In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, Key Trends, and Forecast 2025-2034
Neurofibromatosis Type 1
The rising occurrence of spontaneous (de novo) mutations is expected to boost the growth of the neurofibromatosis type 1 (NF1) market. Spontaneous mutations occur due to errors in DNA replication or environmental factors, rather than being inherited. In NF1, the high mutation rate in the NF1 gene contributes to new cases, even without a family history. For example, a study published in Molecular Biology and Evolution in August 2023 identified numerous de novo mutations, indicating a significant genetic contribution to the development of NF1. As spontaneous mutations continue to play a key role in NF1, the market for NF1-related treatments is expected to grow.
Get Your Neurofibromatosis Type 1 Market Report Here:
https://www.thebusinessresearchcompany.com/report/neurofibromatosis-type-1-global-market-report
What Is the projected market size and growth rate for the neurofibromatosis type 1 market?
The neurofibromatosis type 1 (NF1) market has experienced strong growth, increasing from $8.06 billion in 2024 to $8.86 billion in 2025 at a CAGR of 9.9%. Growth drivers include rising awareness, increased healthcare expenditure, population growth, favorable government policies, and advancements in medical infrastructure.
The neurofibromatosis type 1 (NF1) market is expected to grow substantially, reaching $12.77 billion by 2029, at a CAGR of 9.6%. Growth factors include a rising number of blood cancer cases, increasing prevalence of plexiform tumors and nerve sheath tumors, and growing adoption of neurofibromatosis therapeutics. Key trends in the forecast period will involve continued research and development, new therapy discoveries, improvements in diagnostic methods, tumor-specific treatment approaches, and innovative drug development.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp
What new trends are reshaping the neurofibromatosis type 1 market and its opportunities?
In the neurofibromatosis type 1 (NF1) market, companies are introducing innovative products like kinase inhibitors to improve targeted treatment options and patient outcomes. For example, in May 2023, AstraZeneca plc, a UK-based pharmaceutical company, received approval in China for Koselugo (selumetinib), the first drug approved to treat symptomatic, inoperable plexiform neurofibromas in pediatric NF1 patients aged three and older. This approval expands targeted treatment availability in China and offers a non-surgical alternative for managing NF1-associated tumors, improving the quality of life for patients.
What major market segments define the scope and growth of the neurofibromatosis type 1 market?
The neurofibromatosis type 1 market covered in this report is segmented -
1) By Treatment: Medication, Surgery, Radiation Therapy, Other Treatments
2) By Disease Type: Plexiform Neurofibromas, Cutaneous Neurofibromas, Optic Gliomas, Other Diseases
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
4) By End Users: Hospitals, Speciality Clinics, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Medication: Targeted Therapy, Pain Management Medications, Anticonvulsants
2) By Surgery: Tumor Removal Surgery, Nerve Decompression Surgery
3) By Radiation Therapy: Stereotactic Radiosurgery, External Beam Radiation Therapy
4) By Other Treatments: Physical Therapy, Genetic Counseling, Psychological Support And Counseling
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21230
Which region dominates the neurofibromatosis type 1 market?
North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurofibromatosis type 1 market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Which key market leaders are driving the neurofibromatosis type 1 industry growth?
Major companies operating in the neurofibromatosis type 1 market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Shanghai Fosun Pharmaceutical (Group) Co. Ltd, BeiGene Ltd., BioMarin Pharmaceutical Inc, Exelixis Inc., Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Onclive LLC, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc.
Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=21230&type=smp
What Is Covered In The Neurofibromatosis Type 1 Global Market Report?
•Market Size Forecast: Examine the neurofibromatosis type 1 market size across key regions, countries, product categories, and applications.
•Segmentation Insights: Identify and classify subsegments within the neurofibromatosis type 1 market for a structured understanding.
•Key Players Overview: Analyze major players in the neurofibromatosis type 1 market, including their market value, share, and competitive positioning.
•Growth Trends Exploration: Assess individual growth patterns and future opportunities in the neurofibromatosis type 1 market.
•Segment Contributions: Evaluate how different segments drive overall growth in the neurofibromatosis type 1 market.
•Growth Factors: Highlight key drivers and opportunities influencing the expansion of the neurofibromatosis type 1 market.
•Industry Challenges: Identify potential risks and obstacles affecting the neurofibromatosis type 1 market.
•Competitive Landscape: Review strategic developments in the neurofibromatosis type 1 market, including expansions, agreements, and new product launches.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release In-Depth Analysis of the Neurofibromatosis Type 1 Market: Growth Opportunities, Key Trends, and Forecast 2025-2034 here
News-ID: 3934292 • Views: …
More Releases from The Business Research Company
Company Registration Service Market Landscape 2025: Forecast Data and Growth Str …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Company Registration Service Market Through 2025?
The market size for company registration services has seen robust growth in the recent past. The market is projected to expand from $10.67 billion in 2024 to $11.55 billion in 2025, exhibiting a compound annual growth…
Comprehensive 2025 Commercial Toilet Partition Market Overview: Trends, Forecast …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Toilet Partition Market Through 2025?
In recent years, the market size for commercial toilet partitions has significantly expanded. The forecast predicts a rise from $1.82 billion in 2024 to $1.95 billion in 2025, with a compound annual growth rate (CAGR) of…
Key Trends Influencing the Growth of the Commercial Insurance For Small And Medi …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Commercial Insurance For Small And Medium-Sized Enterprises (SMEs) Market Through 2025?
The market size of commercial insurance for small and medium-sized enterprises (SMEs) has seen substantial growth over the recent years. A rise from $111.83 billion in 2024 to $119.76 billion in…
Growing Focus On Reducing Greenhouse Gas Emissions Driving The Market Growth Due …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Combustion Emissions Analyzer Market Through 2025?
In the past few years, the market size for combustion emissions analyzer has seen robust growth. It is projected to increase from $1.02 billion in 2024 to $1.09 billion in 2025, with a compound annual growth…
More Releases for NF1
Neurofibromatosis Type 1 Market Expected to Gain Momentum Through 2034, Accordin …
The Key Neurofibromatosis Type 1 Companies in the market include - AstraZeneca and Merck, SpringWorks Therapeutics, Healx, Pasithea Therapeutics, Fosun Pharmaceutical, NFlection Therapeutics, and others.
DelveInsight's "Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Neurofibromatosis Type 1, historical and forecasted epidemiology as well as the Neurofibromatosis Type 1 market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and…
The NF1-PN Market Size in 7MM to Witness Notable Growth, Expanding from USD 380 …
The the emergence of new transformative NF1-PN treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks Therapeutics), HLX-1502 (Healx), FCN-159 (Fosun Pharmaceutical), and AS-004 (Pasithea Therapeutics), and others.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new transformative treatments such as KOSELUGO (AstraZeneca and Merck), Mirdametinib (SpringWorks…
Strong Growth Ahead: Neurofibromatosis Type 1 Market Size To Grow At Arecord 9.6 …
We've updated all our reports with current data on tariff changes, trade developments, and supply chain shifts affecting key industries.
How Big Is the Neurofibromatosis Type 1 Market Size Expected to Be by 2034?
In recent times, the growth of the neurofibromatosis type 1 (NF1) market size has been robust. The market is predicted to escalate from $8.06 billion in 2024 to $8.86 billion in 2025, exhibiting a compound annual growth rate…
Neurofibromatosis Type 1 Pipeline: Emerging Targeted Therapies and Gene-Based Ap …
The treatment landscape for Neurofibromatosis Type 1 (NF1), a rare genetic disorder characterized by nerve sheath tumors, skin changes, and other systemic complications, is undergoing a pivotal transformation. Historically limited to symptomatic and surgical management, recent advances are driving the development of disease-modifying therapies that target the underlying genetic and molecular mechanisms. With no curative treatments available, there is a growing focus on MEK inhibitors, RAS/MAPK pathway modulators, and gene…
The NF1-PN Market in 7MM to Witness Notable Growth, Expanding from USD 380 milli …
The ongoing NF1-PN drug development pipeline features additional MEK inhibitors, including Mirdametinib (SpringWorks Therapeutics), FCN-159 (Fosun Pharmaceutical), and PAS-004 (Pasithea Therapeutics). Additionally, HLX-1502 (Healx) is an emerging investigational therapy that provides a novel treatment approach for NF1 patients.
The Neurofibromatosis type 1-associated Plexiform Neurofibromas market across the 7MM is expected to surge owing to an increased awareness, advancements in diagnostic techniques, greater accessibility to genetic testing, and the emergence of new…
Simpli- Automation and Neuro Force One Announce Commencement of Pre-Clinical Tri …
Scottsdale, AZ - June 3, 2024 - Simpli- Automation and Neuro Force One (NF1) proudly announce the initiation of pre-clinical trials for Provectus Trademark , an innovative AI-powered olfactory sensor technology developed by Simpli- Automation. This collaborative endeavor represents a signicant leap forward in health monitoring, diagnostics, and human performance enhancement.
Provectus Trademark , spearheaded by Simpli- Automation, aims to enhance health, wellness, remediation and human performance by providing holistic analyses…
